Press Releases Amarin Corporation plc

Equities

AMRN

US0231112063

Real-time Estimate Cboe BZX Other stock markets 03:51:24 2024-04-29 pm EDT			5-day change	1st Jan Change
0.874 ^USD	-0.10%		+1.72%	+1.22%

Apr. 19	European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down	MT
Apr. 18	European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event	Apr. 24	GL
Amarin Announces Results of Annual General Meeting of Shareholders	Apr. 22	GL
Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024	Apr. 15	GL
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24	Apr. 08	GL
New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups	Apr. 08	AQ
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups	Apr. 06	AQ
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups	Apr. 06	GL
Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe	Apr. 03	GL
Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe	Apr. 03	AQ
Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo	Mar. 25	GL
Amarin: Q4 Earnings Snapshot	Feb. 29	AQ
Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	Feb. 29	GL
Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024	Feb. 15	GL
HLS Announces that Vascepa is now reimbursed by British Columbia's Provincial Drug Plan	Feb. 07	AQ
Amarin Chairman & CEO Issue Letter to Shareholders	Jan. 22	GL
Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024	Jan. 10	GL
Amarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference	Dec. 11	GL
New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline	Nov. 12	AQ
New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline	Nov. 12	GL
AMARIN APPOINTS JONATHAN PROVOOST EXECUTIVE VICE PRESIDENT, CHIEF LEGAL AND COMPLIANCE OFFICER	Nov. 01	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Amarin Corporation plc

Equities

AMRN

US0231112063

Press Releases

Filters